Open Targets
@OpenTargets
Public-private partnership using human genetics and genomics data for systematic drug target identification and prioritisation We're on Bluesky @opentargets.org
🚨New preprint just dropped 🚨 medrxiv.org/content/10.110… The main output from my PhD is finally public and we’re SUPER excited about the findings! If you’re interested in what we learnt about IBD with a massive 700+ sample sc-eQTL dataset of the gut, read on!
Delighted to share the first preprint of my postdoc in the @anderson_carl lab medrxiv.org/content/10.110…! 🚨 A super exciting study I co-led with the very talented @Tobioinformatic. Stay tuned to discover what we learned about genetic susceptibility to complex diseases. A 🧬🧵 1/
Thrilled to share the latest preprint from my lab: medrxiv.org/content/10.110…. Co-led by @Tobioinformatic and @Bradleyomics, supervised by myself and @IBD_MB, we generated IBDverse💫 - gaining insights into genetic susceptibility and pathology of inflammatory bowel disease (IBD).
If EMBL-EBI data resources have saved you time & effort, now is your chance to give back! Fill in a 15-minute survey to help us: 🌍Demonstrate the real-world impact of these resources 🧠Understand your needs 🌟Secure continued funding Closes 16 July 👉 surveymonkey.com/r/QGFMBH8?chan…]
Register for our webinar on 23 April! We will introduce the capabilities and use cases of the Open Targets Platform, including our new variant, study, and credible set pages released last week 👀 ebi.ac.uk/training/event…

There are many improvements and new features in the latest @OpenTargets release. Genetics here we go 🚀 New data visualizations, accessible color pallets, and full UI refresh. Not to say, the addition of @observablehq Plot.js s, the upgrade to @vite_js v6. React Router v7 🔜
At the first Integration Day of 2025, we were joined by @drjosephpowell from the Garvan Institute and Tomas Fitzgerald from EMBL-EBI Thank you to both speakers for their time and insights on the topic of drug exposures, and for everyone who joined the day in person and online!

👀 Not long now until the spring (25.03) Platform release… This will introduce variant, study, and credible set data, effectively merging Open Targets Genetics with the Open Targets Platform Do you have any questions or concerns that we can answer when we release?

New preprint from our group @emblebi and the @TVPLab ! We combined pseudotemporal ordering of cross sectional MASLD patient data with network analysis to describe the disease progression and identify a signature of 24 plasma biomarkers for patient staging biorxiv.org/content/10.110…